Table 1 Clinical characteristics and perioperative data for the landiolol and control groups
Control | Landiolol | P value | |
|---|---|---|---|
(n=48) | (n=57) | ||
Age (yr) | 65.7 ± 12.6 | 67.2 ± 11.5 | NS |
NYHA class | 1.9 ± 0.7 | 1.9 ± 0.7 | NS |
BMI | 23.0 ± 4.1 | 23.0 ± 3.4 | NS |
Hypertension | 38 (79.2) | 47 (82.4) | NS |
Diabetes | 14 (29.2) | 18 (31.6) | NS |
Hyperlipidemia | 18 (37.5) | 25 (43.9) | NS |
Previous CHF | 22 (45.8) | 23 (40.4) | NS |
Previous MI | 7 (14.6) | 12 (21.1) | NS |
Previous AF | 8 (16.7) | 10 (17.5) | NS |
LV Ejection fraction (%) | 60.5 ± 14.7 | 56.4 ± 15.2 | NS |
Preoperative ACE inhibitor use | 38 (79.2) | 37 (64.9) | NS |
Preoperative β-blocker use | 24 (50.0) | 29 (50.9) | NS |
Postoperative β-blocker use | 16 (33.3) | 41 (71.9) | <0.0001 |
Preoperative Cr (mg/dL) | 1.1 ± 1.8 | 1.3 ± 1.6 | NS |
Preoperative % VC | 95 ± 21 | 94 ± 19 | NS |
Preoperative FEV 1.0% | 82 ± 15 | 82 ± 14 | NS |
On-pump CABG | 5 (10.4) | 9 (15.8) | NS |
Off-pump CABG | 14 (29.2) | 27 (47.4) | NS |
Valve surgery | |||
AVR | 16 (33.3) | 12 (21.1) | NS |
MVR | 3 (6.3) | 2 (3,5) | NS |
MVP | 9 (18.8) | 6 (10.5) | NS |
TVP | 1 (2.1) | 1 (1.8) | NS |
Operating time (min) | 344 ± 78 | 334 ± 86 | NS |
Blood loss (mL) | 1159 ± 1036 | 1197 ± 1246 | NS |
Fluid and blood infusion volume (mL) | 5471 ± 1657 | 5405 ± 1948 | NS |
Urine volume (mL) | 1283 ± 933 | 1270 ± 948 | NS |
No. of patients receiving intraoperative remifentanil | 32 (66.7) | 39 (68.4) | NS |
Intraoperative remifentanil dose (μg/kg/min) | 0.18 ± 0.06 | 0.21 ± 0.07 | NS |
Postoperative AF | 12 (25.0) | 5 (8.8) | 0.02 |
Time of onset of new AF (d) | 2.2 ± 1.0 | 3.0 ± 1.2 | NS |
Length of ICU stay (d) | 3.5 ± 2.0 | 3.0 ± 2.1 | NS |
Time to extubation (hr) | 20.9 ± 41.6 | 16.0 ± 29.1 | NS |
Postoperative complications | |||
Pulmonary edema | 6 (12.5) | 7 (12.3) | NS |
Stroke | 1 ((2.1) | 0 | NS |
Seizures | 1 (2.1) | 1 (1.8) | NS |
Renal failure | 0 | 1 (1.8) | NS |